June 30, 2026 | 52-Week Highs and Lows

52-Week Highs

ASTH | Astrana Health | $45.08 Astrana Health, a value-based care provider focused on Medicare and Medicaid populations, reached a new 52-week high on strong operational results and multiple analyst target raises.

FDMT | 4D Molecular Therapeutics | $13.33 4D Molecular Therapeutics pushed to a fresh high as enthusiasm continues to build around its gene therapy pipeline and upcoming ophthalmology catalysts.

IBB | iShares Biotechnology ETF | $189.85 The iShares Biotechnology ETF reached a new peak as the broader biotech sector rallied on clinical progress and continued M&A activity.

CLYM | Climb Bio | $13.58 Climb Bio advanced on continued Phase 2 progress for its anti-CD19 monoclonal antibody, budoprutug, in kidney disease and autoimmune indications.

MRK | Merck | $129.96 Merck reached a new high on continued strength from Keytruda and growing momentum across its oncology pipeline.

PGEN | Precigen | $6.04 Precigen climbed on updates across its gene and cell therapy pipeline.

ABSI | Absci | $12.06 Absci gained as investors continued rewarding advances in its AI-driven biologics discovery platform.

BDSX | Biodesix | $24.34 Biodesix reached a new high on expanding adoption of its blood-based lung cancer diagnostic platform.

MPLT | MapLight Therapeutics | $34.52 MapLight Therapeutics advanced on continued clinical progress across its novel CNS disorder programs.

GHRS | GH Research | $28.96 GH Research moved higher amid continued progress across its neuroscience pipeline.

BIOA | BioAge Labs | $25.80 BioAge Labs gained on continued development across its metabolic disease and healthy aging pipeline.

NRIX | Nurix Therapeutics | $24.03 Nurix climbed following updates to its targeted protein degradation programs in oncology and autoimmune diseases.

DFTX | Definium Therapeutics | $47.20 Definium Therapeutics surged following strong Phase 3 data for its LSD-based candidate targeting depression and broader brain health programs.

ETON | Eton Pharmaceuticals | $36.95 Eton Pharmaceuticals reached a new high as its rare disease specialty pharmaceutical portfolio continued to expand.

AMLX | Amylyx Pharmaceuticals | $18.75 Amylyx advanced on continued progress across its neurology pipeline.

LFST | LifeStance Health | $10.63 LifeStance gained as demand for outpatient mental health services continued to strengthen.

CLDX | Celldex Therapeutics | $37.54 Celldex reached a fresh high on continued momentum across its antibody therapy clinical programs.

PDLB | Ponce Financial Group | $20.01 Ponce Financial Group, the holding company for Ponce Bank, advanced alongside broader strength across regional banking stocks.

MBX | MBX Biosciences | $55.00 MBX Biosciences climbed on continued progress across its precision peptide pipeline, including Phase 3 Canvuparatide for hypoparathyroidism and obesity development programs.

MGTX | MeiraGTx | $12.56 MeiraGTx advanced following updates across its gene therapy pipeline.

ELVN | Elevian | $51.06 Elevian gained on continued progress in regenerative medicine and inflammatory disease programs.

NBIX | Neurocrine Biosciences | $171.43 Neurocrine Biosciences reached a new high on strong commercial neurology sales and continued pipeline execution.

BLFS | BioLife Solutions | $30.00 BioLife Solutions climbed as demand remained strong for its cell and gene therapy manufacturing solutions.

IBBQ | IBBQ Biotech ETF | $32.62 IBBQ reached a new high as the biotechnology sector continued its broad-based rally.

MIRM | Mirum Pharmaceuticals | $125.39 Mirum Pharmaceuticals advanced on continued commercial success and pipeline growth in rare liver diseases.

EXEL | Exelixis | $55.91 Exelixis reached a new high on continued Cabometyx sales growth and encouraging subgroup data from the CABINET trial.

ORKA | Oruka Therapeutics | $95.38 Oruka Therapeutics climbed on continued progress across its IL-23 and IL-17 monoclonal antibody programs for psoriasis.

CMPS | Compass Pathways | $15.40 Compass Pathways advanced as investors continued following development of its psilocybin-based treatment for depression.

DNLI | Denali Therapeutics | $26.19 Denali Therapeutics gained on continued confidence in its blood-brain barrier platform and neurodegenerative disease pipeline.

LXRX | Lexicon Pharmaceuticals | $2.67 Lexicon Pharmaceuticals advanced on continued progress across its small-molecule development programs.

ADPT | Adaptive Biotechnologies | $21.64 Adaptive Biotechnologies moved higher as its immune profiling and genomics platforms continued gaining traction.

GENB | Generate Biomedicines | $17.98 Generate Biomedicines reached a new high as investors continued rewarding its AI-powered generative biology drug discovery platform.

ABCL | AbCellera | $8.42 AbCellera advanced on continued strength in its antibody discovery platform and expanding partnership activity.

CADL | Candel Therapeutics | $10.38 Candel Therapeutics gained on continued progress for CAN-2409 and the initiation of a new Phase 3 lung cancer trial.

DNTH | Dianthus Therapeutics | $97.38 Dianthus Therapeutics reached a new high as investors continued favoring its complement-targeted therapies for severe autoimmune diseases.

XBI | SPDR S&P Biotech ETF | $155.93 The SPDR S&P Biotech ETF reached another 52-week high, highlighting broad participation across small and mid-cap biotechnology.

CYTK | Cytokinetics | $87.35 Cytokinetics advanced on revenue growth and continued positive data for aficamten in hypertrophic cardiomyopathy.

52-Week Lows

NAGE | Niagen Bioscience | $3.27 Niagen Bioscience, focused on NAD+ science and healthy aging, reached a new low following analyst target adjustments after earnings.

CMND | Clearmind Medicine | $2.04 Clearmind Medicine reached a new low as micro-cap psychedelic and mental health companies continued experiencing elevated volatility.

ACTU | Actuate Therapeutics | $1.46 Actuate Therapeutics traded to a new low amid the financing challenges and clinical uncertainty that continue to pressure many early-stage biotechnology companies.

The Tape

Today's tape highlighted the continued leadership of biotechnology.

Both IBB and XBI reached fresh 52-week highs, reinforcing the broad strength seen across the sector. Leadership extended well beyond the large-cap names, with companies spanning oncology, gene therapy, neuroscience, autoimmune disease, precision medicine, AI-enabled drug discovery, diagnostics, and specialty pharmaceuticals all participating in the advance.

Investors continued rewarding companies with meaningful clinical execution, expanding commercial franchises, differentiated technology platforms, and visible late-stage catalysts. At the same time, the 52-week low list remained limited to a handful of small-cap development-stage companies facing financing concerns or lacking near-term catalysts.

The market continues to favor quality, execution, and innovation, while M&A optimism and improving capital flows provide an additional tailwind for the biotechnology sector.